BIJUVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BIJUVA (BIJUVA).
BIJUVA (estradiol and progesterone) is a combination hormone replacement therapy. Estradiol acts by binding to estrogen receptors, which modulate gene transcription and cellular activity, alleviating menopausal symptoms. Progesterone opposes estrogen-induced endometrial proliferation, reducing the risk of endometrial hyperplasia.
| Metabolism | Estradiol is metabolized primarily in the liver via CYP3A4 and CYP1A2 to estrone and estriol, undergoing conjugation (glucuronidation and sulfation). Progesterone is metabolized in the liver via CYP3A4 and CYP2C19 to pregnanolone and pregnanediol, followed by glucuronide conjugation. |
| Excretion | Approximately 70% renal (mostly unchanged drug) and 30% fecal/biliary |
| Half-life | Terminal elimination half-life is approximately 10–12 hours; allows twice-daily dosing for sustained effect |
| Protein binding | Approximately 99% bound primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd ~1.5–2.0 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral bioavailability ~85–90% (with minimal first-pass metabolism) |
| Onset of Action | Oral: ~1–2 hours (time to peak plasma concentrations); clinical effect may be noted within 2–4 hours |
| Duration of Action | Approximately 12 hours (consistent with dosing interval); symptom control maintained with twice-daily administration |
Oral, one capsule twice daily with food. Each capsule contains estradiol 1 mg and progesterone 100 mg.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m2); use with caution. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild (Child-Pugh A) or moderate (Child-Pugh B) impairment, no dosage adjustment is recommended; however, use with caution and monitor liver function. |
| Pediatric use | Safety and efficacy not established in pediatric patients. Not indicated for use in children. |
| Geriatric use | No specific dosage adjustment is required for geriatric patients. However, consider increased risk of thromboembolic events and breast cancer in women >65 years; limit use to shortest duration consistent with treatment goals. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BIJUVA (BIJUVA).
| Breastfeeding | Estradiol and progesterone are excreted in human milk. The estradiol M/P ratio is approximately 0.9; progesterone M/P ratio is approximately 1.0. Exposed infants may experience jaundice, galactorrhea, or breast enlargement. BIJUVA is not recommended during breastfeeding due to potential adverse effects on the infant. |
| Teratogenic Risk | BIJUVA (estradiol/progesterone) is contraindicated in pregnancy. First trimester exposure may be associated with an increased risk of congenital anomalies, including cardiovascular and limb defects, based on data from estrogens. Second and third trimester exposure may be associated with urogenital abnormalities in female fetuses and potential for long-term reproductive effects. Use of progestins in pregnancy has been linked to hypospadias in male fetuses. |
■ FDA Black Box Warning
Estrogen-alone therapy: increased risk of endometrial cancer in women with a uterus. Combination therapy: increased risk of breast cancer, venous thromboembolism, stroke, and dementia (see full prescribing information). BIJUVA is not approved for prevention of dementia.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease (e.g., stroke, MI) or history","Known protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders","Liver impairment or disease","Known or suspected pregnancy","Hypersensitivity to any ingredient"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, PE, and myocardial infarction","Malignancy: increased risk of breast and ovarian cancer, especially with prolonged use","Dementia: increased risk in women 65+ years of age","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Hereditary angioedema","Exacerbation of endometriosis","Fluid retention","Hypothyroidism: estrogen increases thyroxine-binding globulin, may require thyroid dose adjustment","Lipid abnormalities: marked hypertriglyceridemia leading to pancreatitis"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, liver function, signs of thromboembolism, and glucose tolerance. Fetal monitoring includes ultrasound for growth and anatomy if exposure occurs. |
| Fertility Effects | BIJUVA is used for contraception and suppresses ovulation. It is not intended for use during fertility treatment. Fertility may be delayed upon discontinuation due to hormonal suppression. |
| Food/Dietary | Grapefruit and grapefruit juice may increase estradiol levels; avoid concurrent consumption. No other significant food interactions reported. |
| Clinical Pearls | BIJUVA is a combination of estradiol and progesterone indicated for hormone therapy in menopausal women with an intact uterus. It is available as a capsule containing estradiol 1 mg and progesterone 100 mg. The progesterone component protects the endometrium from estrogen-induced hyperplasia. Avoid use in women with known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, or active thromboembolic disorders. Monitor for signs of thromboembolism, including sudden chest pain, dyspnea, or leg swelling. Use lowest effective dose for shortest duration consistent with treatment goals. |
| Patient Advice | Take BIJUVA exactly as prescribed, usually once daily at bedtime to minimize potential dizziness or drowsiness from progesterone. · Do not use if you are pregnant, think you may be pregnant, or are breastfeeding. · Inform your healthcare provider immediately if you experience symptoms of a blood clot, such as chest pain, sudden shortness of breath, or pain/swelling in one leg. · Attend regular check-ups including mammograms and pelvic exams as recommended. · BIJUVA may increase the risk of stroke, heart attack, breast cancer, and dementia. Discuss your personal risks with your doctor. · Swallow capsules whole; do not crush, chew, or open. · Store at room temperature away from moisture and heat. |